In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover Secure dosing routine. More participants might be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Section C, https://abbv-744-in-clinical-tria67902.qodsblog.com/32061410/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results